What can and cannot be concluded from a multifactorial health study in which several interventions are tested simultaneously?
Multifactorial research can reliably measure the effects of several interventions simultaneously, but whether the findings can be generalised depends on how long the follow-up lasted, whether participants were blinded, and whether the interventions had no interaction with one another. For each outcome, consider how large and how durable the observed effect is, not merely whether it is statistically significant.
A factorial study design in which several interventions are tested simultaneously has one major advantage: you can measure the separate effects of each intervention without needing extra participants. That works, however, only if the interventions do not reinforce or counteract one another. In the three randomised trials discussed here that condition was met in each case: the researchers routinely checked for so-called interaction before interpreting the results of each intervention separately.
What the studies actually show differs considerably from one intervention to the next. The GRASP trial in shoulder pain found that six sessions of exercise therapy over 12 months added nothing beyond a single well-structured advice consultation. A corticosteroid injection did produce improvement, but only during the first eight weeks. After that the advantage had disappeared. This is an important distinction: a short-term effect is not the same as genuine recovery. Furthermore, the long-term safety of repeated injections was not examined within the 12-month follow-up.
For pregnancy nausea, the acupuncture/doxylamine trial showed that both acupuncture and the anti-emetic doxylamine-pyridoxine modestly reduced symptoms. The combination worked better than either treatment alone. However, there was also a concerning signal: the anti-emetic was associated with an increased risk of delivering a small-for-gestational-age baby. The confidence interval was wide, so this remains a signal that calls for further research, not an established fact. Anyone who is pregnant and wants to know whether this medication is safe would do well to discuss it with their doctor.
In the DO-HEALTH study of healthy older adults with a mean age of 75 years, vitamin D3 had a small but measurable positive effect on bone density in the hip. Omega-3 fatty acids and a home-based strength programme had no demonstrable effect on bone density. The clinical significance of the vitamin D effect is uncertain, however: the measured difference was very small.
The most important methodological lesson: a factorial design makes it possible to answer several questions at once, but it does not provide a definitive answer on long-term safety when the follow-up period is too short. Moreover, when participants and clinicians are not blinded, as was the case in the GRASP trial, the risk of unconscious bias remains. That is not a reason to ignore the findings, but it is a reason not to treat them as the final word.
Claims based on three multicentre randomised trials (GRASP, acupuncture/doxylamine, DO-HEALTH) and one systematic review. No meta-analyses were used as a primary source. The safety signal for doxylamine-pyridoxine comes from the same RCT and has a wide confidence interval; cautious interpretation is warranted.